178 related articles for article (PubMed ID: 8723120)
1. Serial examination of 20,248 newborn fetuses and infants: correlations between drug exposure and major malformations.
Queisser-Luft A; Eggers I; Stolz G; Kieninger-Baum D; Schlaefer K
Am J Med Genet; 1996 May; 63(1):268-76. PubMed ID: 8723120
[TBL] [Abstract][Full Text] [Related]
2. [In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam?].
Bonnot O; Vollset SE; Godet PF; d'Amato T; Dalery J; Robert E
Encephale; 2003; 29(6):553-9. PubMed ID: 15029090
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid monotherapy in pregnancy and major congenital malformations.
Jentink J; Loane MA; Dolk H; Barisic I; Garne E; Morris JK; de Jong-van den Berg LT;
N Engl J Med; 2010 Jun; 362(23):2185-93. PubMed ID: 20558369
[TBL] [Abstract][Full Text] [Related]
4. Maternal asthma, asthma medication use, and the risk of congenital heart defects.
Lin S; Herdt-Losavio M; Gensburg L; Marshall E; Druschel C
Birth Defects Res A Clin Mol Teratol; 2009 Feb; 85(2):161-8. PubMed ID: 19067406
[TBL] [Abstract][Full Text] [Related]
5. Threatened abortion, hormone therapy and malformed embryos.
Matsunaga E; Shiota K
Teratology; 1979 Dec; 20(3):469-80. PubMed ID: 542899
[TBL] [Abstract][Full Text] [Related]
6. Maternal diabetes: an independent risk factor for major cardiovascular malformations with increased mortality of affected infants.
Loffredo CA; Wilson PD; Ferencz C
Teratology; 2001 Aug; 64(2):98-106. PubMed ID: 11460261
[TBL] [Abstract][Full Text] [Related]
7. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies.
Park-Wyllie L; Mazzotta P; Pastuszak A; Moretti ME; Beique L; Hunnisett L; Friesen MH; Jacobson S; Kasapinovic S; Chang D; Diav-Citrin O; Chitayat D; Nulman I; Einarson TR; Koren G
Teratology; 2000 Dec; 62(6):385-92. PubMed ID: 11091360
[TBL] [Abstract][Full Text] [Related]
8. [Epidemiology of congenital malformations at the Hospital Pedro García Clara, Ciudad Ojeda, Venezuela].
Pineda-Del Villar L; Martínez-Basalo MC; Delgado W; Prieto-Carrasquero M; Villasmil Y
Invest Clin; 1994 Mar; 35(1):19-34. PubMed ID: 8054378
[TBL] [Abstract][Full Text] [Related]
9. Maternal periconceptional illicit drug use and the risk of congenital malformations.
van Gelder MM; Reefhuis J; Caton AR; Werler MM; Druschel CM; Roeleveld N;
Epidemiology; 2009 Jan; 20(1):60-6. PubMed ID: 19057385
[TBL] [Abstract][Full Text] [Related]
10. Maternal febrile illnesses, medication use, and the risk of congenital renal anomalies.
Abe K; Honein MA; Moore CA
Birth Defects Res A Clin Mol Teratol; 2003 Nov; 67(11):911-8. PubMed ID: 14745928
[TBL] [Abstract][Full Text] [Related]
11. Maternal flu or fever, medication use, and neural tube defects: a population-based case-control study in Northern China.
Li Z; Ren A; Liu J; Pei L; Zhang L; Guo Z; Li Z
Birth Defects Res A Clin Mol Teratol; 2007 Apr; 79(4):295-300. PubMed ID: 17216625
[TBL] [Abstract][Full Text] [Related]
12. [A risk analysis of congenital defects due to drug intake during pregnancy. Spanish Collaborative Study of Congenital Malformations].
Martínez-Frías ML
Med Clin (Barc); 1999 Jan; 112(2):41-4. PubMed ID: 10065427
[TBL] [Abstract][Full Text] [Related]
13. [A study on the risk factors of congenital urogenital malformations].
Wang J; Wang B; Zhao J
Zhonghua Liu Xing Bing Xue Za Zhi; 2001 Jun; 22(3):176-8. PubMed ID: 11860870
[TBL] [Abstract][Full Text] [Related]
14. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study.
Ofori B; Oraichi D; Blais L; Rey E; Bérard A
Birth Defects Res B Dev Reprod Toxicol; 2006 Aug; 77(4):268-79. PubMed ID: 16929547
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of congenital diaphragmatic hernia: a population-based study in Western Australia.
Colvin J; Bower C; Dickinson JE; Sokol J
Pediatrics; 2005 Sep; 116(3):e356-63. PubMed ID: 16140678
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin.
Pollack PS; Shields KE; Burnett DM; Osborne MJ; Cunningham ML; Stepanavage ME
Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):888-96. PubMed ID: 16163683
[TBL] [Abstract][Full Text] [Related]
17. A population-based case-control study of the safety of oral anti-tuberculosis drug treatment during pregnancy.
Czeizel AE; Rockenbauer M; Olsen J; Sørensen HT
Int J Tuberc Lung Dis; 2001 Jun; 5(6):564-8. PubMed ID: 11409585
[TBL] [Abstract][Full Text] [Related]
18. Maternal pesticide exposure from multiple sources and selected congenital anomalies.
Shaw GM; Wasserman CR; O'Malley CD; Nelson V; Jackson RJ
Epidemiology; 1999 Jan; 10(1):60-6. PubMed ID: 9888281
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the international Clearinghouse of birth defects surveillance and research.
Lisi A; Botto LD; Robert-Gnansia E; Castilla EE; Bakker MK; Bianca S; Cocchi G; de Vigan C; Dutra Mda G; Horacek J; Merlob P; Pierini A; Scarano G; Sipek A; Yamanaka M; Mastroiacovo P
Reprod Toxicol; 2010 Jul; 29(4):433-42. PubMed ID: 20347959
[TBL] [Abstract][Full Text] [Related]
20. Selection of controls in case-control studies on maternal medication use and risk of birth defects.
Bakker MK; de Walle HE; Dequito A; van den Berg PB; de Jong-van den Berg LT
Birth Defects Res A Clin Mol Teratol; 2007 Sep; 79(9):652-6. PubMed ID: 17668455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
